Inactive Instrument

Sangui Biotech International, Inc. Stock price Other OTC

Equities

SGBI

US80105B1017

Biotechnology & Medical Research

Sales 2021 65.58K Sales 2022 69.19K Capitalization 3.09M
Net income 2021 - Net income 2022 - EV / Sales 2021 90.6 x
Net Debt 2021 790K Net Debt 2022 795K EV / Sales 2022 56.1 x
P/E ratio 2021
-25.6 x
P/E ratio 2022
-51.8 x
Employees -
Yield 2021 *
-
Yield 2022
-
Free-Float 86.94%
More Fundamentals * Assessed data
Dynamic Chart
Sangui Biotech International, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023 CI
Sangui Biotech International, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023 CI
Sangui Biotech International, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023 CI
Sangui Biotech International, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022 CI
Sangui Biotech International, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2022 CI
Sangui Biotech International, Inc. Reports Earnings Results for the Full Year Ended June 30, 2022 CI
Sangui Biotech International, Inc. Auditor Raises 'Going Concern' Doubt CI
Sangui Biotech International, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2022 CI
Sangui Biotech International, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2021 CI
Sangui Biotech International, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2021 CI
Sangui Biotech International, Inc. Reports Earnings Results for the Full Year Ended June 30, 2021 CI
Sangui Biotech International, Inc. Auditor Raises 'Going Concern' Doubt CI
Sangui Biotech International, Inc. Reports Earnings Results for the Third Quarter Ended March 31, 2021 CI
Sangui Biotech International, Inc. Reports Earnings Results for the Second Quarter Ended December 31, 2020 CI
Sangui Biotech International, Inc. Announces Earnings Results for the First Quarter Ended September 30, 2020 CI
More news
Managers TitleAgeSince
Chief Executive Officer 62 05-02-06
Members of the board TitleAgeSince
Chief Executive Officer 62 05-02-06
Director/Board Member 68 08-12-17
More insiders
Sangui Biotech International, Inc. focuses on the development of pharmaceutical, medical and cosmetic products. The Company develops its products through its German subsidiary, SanguiBioTech AG (Sangui GmbH). It is engaged in seeking to market and selling its products through partnerships with industry partners across the world. It focuses on the development of oxygen carriers capable of providing oxygen transport in humans in the event of acute and/or chronic lack of oxygen due to arterial occlusion, anemia or blood loss whether due to surgery, trauma, or other causes. It focuses its development and commercialization efforts on such artificial oxygen carriers by reproducing and synthesizing polymers out of native hemoglobin of defined molecular sizes. It offers external applications of oxygen transporters in the medical and cosmetic fields in the form of sprays for the healing of chronic wounds and of gels and emulsions for the regeneration of the skin.
More about the company
  1. Stock
  2. Equities
  3. Stock Sangui Biotech International, Inc.
  4. Stock Sangui Biotech International, Inc. - Other OTC